ArticleCureus2025
Procalcitonin as a Potential Prognostic Marker in Advanced Hodgkin Lymphoma: A Case-Based Perspective.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report examines the potential role of procalcitonin (PCT) as a prognostic biomarker in classic Hodgkin lymphoma (cHL), focusing on a 61-year-old male with advanced disease and systemic inflammation. The patient presented with progressive dyspnea, bilateral pleural effusions, and mediastinal lymphadenopathy. Imaging revealed hepatic, splenic, and adrenal involvement, consistent with stage IV HL. Axillary lymph node biopsy confirmed lymphocyte-rich cHL, with immunohistochemical markers including CD30, CD15, PAX5, Ki-67, MUM1, and BCL6. Despite broad-spectrum antimicrobial therapy and a comprehensive infectious workup, the patient exhibited rising PCT levels (peak 4.5 ng/mL) and declining albumin levels, with no microbiological evidence of infection. This persistent elevation of PCT in the absence of confirmed infection suggests a possible link between HL-associated inflammation and PCT production, potentially mediated by cytokine-driven paraneoplastic processes. The patient's clinical deterioration and eventual death underscore the aggressive nature of extranodal HL and raise questions about the utility of PCT as a surrogate marker of disease activity. While PCT is traditionally used to identify bacterial infections, its elevation in this case may reflect tumor-induced systemic inflammation. This observation supports further investigation into the prognostic relevance of PCT in HL, particularly in older patients with extensive disease burden. Clinicians should interpret elevated PCT levels cautiously in oncologic settings and consider malignancy-related inflammation as a contributing factor. Future studies are needed to evaluate PCT dynamics across HL subtypes and treatment phases, potentially integrating it into multimodal prognostic models. This report suggests that PCT may offer valuable insights into disease progression and inflammatory status in HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.